Prognostic value of the mRNA expression of members of the HSP90 family in non-small cell lung cancer
Prognostic value of the mRNA expression of members of the HSP90 family in non-small cell lung cancer
复制标题
HSP90家族成员mRNA表达对非小细胞肺癌的预后价值
DOI：
10.3892/etm.2019.7228
复制
发表时间：
2019-04-01
影响因子：
2.7
通讯作者：
Wang, Rensheng
中科院分区：
文献类型：
--
作者：
Liu, Kang;Kang, Min;Wang, Rensheng
本研究的目的是探讨热休克蛋白(HSP)90家族成员在非小细胞肺癌(NSCLC)患者中的潜在预后价值。从Kaplan-Meier绘图仪数据库中获得的1926例非小细胞肺癌患者的mRNA表达谱被纳入研究中。HSP90AA1基因的高表达与所有非小细胞肺癌患者的总生存率[危险比(HR)1.21；95%可信区间(CI)：1.06~1.37；P=0.004]以及腺癌患者(ADE；HR，1.3；95%CI：1.02~1.65；P=0.034)显著相关，但与鳞癌患者的总体生存率(HR，1.08；95%CI：0.85~1.38；P=0.51)无关。HSP90AB1和HSP90B1mRNA的高表达与肺SCC和ADE患者以及单独肺ADE患者的OS发生率显著相关。相比之下，肿瘤坏死因子受体相关蛋白1mRNA的高表达与所有非小细胞肺癌患者以及ADE患者的OS发生率显著相关(HR，0.88；95%CI：0.77~0.99；P=0.041)。在分层生存分析中，HSP90AA1、HSP90AB1和HSP90B1的高表达预示着I期NSLCC患者预后不良，提示这些基因可能是与分期无关的预后指标。由于HSP90AA1、HSP90AB1、HSP90B1和TRAP1的高表达与NSCLC患者的预后不良有关，这些HSP90成员可能成为NSCLC治疗的潜在预后生物标志物和药物靶点。
The aim of the present study was to investigate the potential prognostic value of members of the heat shock protein (HSP)90 family in non-small cell lung cancer (NSCLC) patients. The mRNA expression profiles of 1,926 NSCLC patients, which was available from the Kaplan-Meier plotter database, were included in the study. High expression of HSP90AA1 mRNA was significantly associated with a poorer rate of overall survival (OS) for all NSCLC patients [hazard ratio (HR), 1.21; 95% confidence interval (CI): 1.06–1.37; P=0.004], as well as for patients with adenocarcinoma (ADE; HR, 1.3; 95% CI: 1.02–1.65; P=0.034), but no significant correlation was identified for squamous cell carcinoma (SCC) patients (HR, 1.08; 95% CI: 0.85–1.38; P=0.51). High expression of HSP90AB1 and HSP90B1 mRNA was significantly associated with poorer rates of OS in lung SCC and ADE patients combined, as well as in lung ADE patients alone. By contrast, high expression of tumor necrosis factor receptor-associated protein 1 (TRAP1) mRNA was significantly associated with improved OS rates in all NSCLC patients combined (HR, 0.88; 95% CI: 0.77–0.99; P=0.041), as well as ADE patients. In stratified survival analysis, a high expression of HSP90AA1, HSP90AB1 and HSP90B1 predicted poor prognosis in stage I NSLCC patients, suggesting that these genes may serve as stage-independent prognostic indicators. As an elevated expression of HSP90AA1, HSP90AB1, HSP90B1 and TRAP1 was associated with poorer OS outcomes in patients with NSCLC, these HSP90 members may be potential prognostic biomarkers and drug targets for the treatment of NSCLC.